Efficacy and Tolerability of Limited Field Radiotherapy with Concurrent Capecitabine in Locally Advanced Pancreatic Cancer

Clinical Oncology

Volumn 22, Issue 7, 2010, Pages 570-577

  Jackson, A S N ^a   Jain, P ^a   Watkins, G R ^a   Whitfield, G A ^a   Green, M M ^a   Valle, J ^b   Taylor, M B ^b   Dickinson, C ^a   Price, P M ^a   Saleem, A ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Capecitabine; Chemoradiotherapy; Limited field; Locally advanced pancreatic cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CISPLATIN; FLUOROURACIL; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PAIN; CANCER RADIOTHERAPY; CHOLANGITIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; MALE; NAUSEA; PANCREAS CANCER; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION FIELD; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR VOLUME; VOMITING;

EID: 77955661981     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.06.007     Document Type: Article

References (45)

1. Crane C.H., Varadhachary G., Settle S.H., Fleming J.B., Evans D.B., Wolff R.A. The integration of chemoradiation in the care of patients with localized pancreatic cancer. Cancer Radiother 2009, 13(2):123-143.
2. Mukherjee S., Hudson E., Reza S., Thomas M., Crosby T., Maughan T. Pancreatic cancer within a UK cancer network with special emphasis on locally advanced non-metastatic pancreatic cancer. Clin Oncol (R Coll Radiol) 2008, 20(7):535-540.
3. Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Gastrointestinal Tumor Study Group. Cancer 1985, 56(11):2563-2568.
4. Moertel C.G., Frytak S., Hahn R.G., et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-fluorouracil), and high dose radiation+5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 1981, 48(8):1705-1710.
5. Haddock M.G., Swaminathan R., Foster N.R., et al. Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. J Clin Oncol 2007, 25(18):2567-2572.
6. Li C.P., Chao Y., Chi K.H., et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 2003, 57(1):98-104.
7. Okusaka T., Ito Y., Ueno H., et al. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer 2004, 91(4):673-677.
8. Okusaka T., Okada S., Tokuuye K., et al. Lack of effectiveness of radiotherapy combined with cisplatin in patients with locally advanced pancreatic carcinoma. Cancer 2001, 91(7):1384-1389.
9. Park J.K., Ryu J.K., Lee J.K., et al. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer. Pancreas 2006, 33(4):397-402.
10. Wilkowski R., Thoma M., Bruns C., Wagner A., Heinemann V. Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer. JOP 2006, 7(4):349-360.
11. Wilkowski R., Thoma M., Duhmke E., Rau H.G., Heinemann V. Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma. Int J Radiat Oncol Biol Phys 2004, 58(3):768-772.
12. Crane C.H. In response to Li et al.: Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiol Oncol Biol Phys 2003;57:98-104. Int J Radiat Oncol Biol Phys 2004, 58(3):1009. author reply 1009-1010.
13. Crane C.H., Janjan N.A., Evans D.B., et al. Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol 2001, 29(1):9-18.
14. Sawaki A., Hoki N., Ito S., et al. Clinical impact of radiotherapy for locally advanced pancreatic cancer. J Gastroenterol 2009, 44:1209-1214.
15. Chauffert B., Mornex F., Bonnetain F., et al. Phase III trial comparing intensive induction chemoradiotherapy (60Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008, 19(9):1592-1599.
16. Loehrer P.J., Powell M.E., Cardenes H.R., et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol 2008, 26(15S):4506.
17. Passantino L., Patruno R., Valerio P., et al. Thymidine phosphorylase profiles in nonmalignant and malignant pancreatic tissue. Potential therapeutic role of capecitabine on tumoral and endothelial cells and tumor-infiltrating macrophages. Immunopharmacol Immunotoxicol 2005, 27(1):95-107.
18. Van Cutsem E., Peeters M. Oral fluoropyrimidines in colorectal cancer. Semin Oncol 2000, 27(5 Suppl. 10):91-95.
19. Blanquicett C., Saif M.W., Buchsbaum D.J., et al. Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clin Cancer Res 2005, 11(24 Pt 1):8773-8781.
20. Das P., Wolff R.A., Abbruzzese J.L., et al. Concurrent capecitabine and upper abdominal radiation therapy is well tolerated. Radiat Oncol 2006, 1:41.
21. Kim H.S., Yi S.Y., Jun H.J., et al. Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer. Anticancer Drugs 2009, 21:17-112.
22. Schneider B.J., Ben-Josef E., McGinn C.J., et al. Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2005, 63(5):1325-1330.
23. Vaishampayan U.N., Ben-Josef E., Philip P.A., et al. A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies. Int J Radiat Oncol Biol Phys 2002, 53(3):675-679.
24. Kawakami H., Uno T., Isobe K., et al. Toxicities and effects of involved-field irradiation with concurrent cisplatin for unresectable carcinoma of the pancreas. Int J Radiat Oncol Biol Phys 2005, 62(5):1357-1362.
25. McGinn C.J., Zalupski M.M., Shureiqi I., et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001, 19(22):4202-4208.
26. Muler J.H., McGinn C.J., Normolle D., et al. Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. J Clin Oncol 2004, 22(2):238-243.
27. Tokuuye K., Sumi M., Kagami Y., et al. Small-field radiotherapy in combination with concomitant chemotherapy for locally advanced pancreatic carcinoma. Radiother Oncol 2003, 67(3):327-330.
28. Yamazaki H., Nishiyama K., Koizumi M., et al. Concurrent chemoradiotherapy for advanced pancreatic cancer: 1,000mg/m2 gemcitabine can be administered using limited-field radiotherapy. Strahlenther Onkol 2007, 183(6):301-306.
29. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988, 80(10):751-755.
30. Klaassen D.J., MacIntyre J.M., Catton G.E., Engstrom P.F., Moertel C.G. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - an Eastern Cooperative Oncology Group study. J Clin Oncol 1985, 3(3):373-378.
31. Saif M.W., Eloubeidi M.A., Russo S., et al. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol 2005, 23(34):8679-8687.
32. Shinchi H., Takao S., Noma H., et al. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2002, 53(1):146-150.
33. Wilkowski R., Thoma M., Schauer R., Wagner A., Heinemann V. Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J Surg 2004, 28(10):1011-1018.
34. Berlin J.D., Adak S., Vaughn D.J., et al. A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296). Oncology 2000, 58(3):215-218.
35. Bramhall S.R., Schulz J., Nemunaitis J., Brown P.D., Baillet M., Buckels J.A. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002, 87(2):161-167.
36. Louvet C., Labianca R., Hammel P., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005, 23(15):3509-3516.
37. Rocha Lima C.M., Green M.R., Rotche R., et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004, 22(18):3776-3783.
38. Ceha H.M., van Tienhoven G., Gouma D.J., et al. Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma. Cancer 2000, 89(11):2222-2229.
39. Ben-Josef E., Shields A.F., Vaishampayan U., et al. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys 2004, 59(2):454-459.
40. Saif M.W., Moody J.S., Russo S.M. Gastrointestinal bleeding associated with concurrent capecitabine and radiotherapy in patients with pancreatic cancer. JOP 2005, 6(4):325-333.
41. Milano M.T., Chmura S.J., Garofalo M.C., et al. Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 2004, 59(2):445-453.
42. Crane C.H., Ellis L.M., Abbruzzese J.L., et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 2006, 24(7):1145-1151.
43. Feng M., Balter J.M., Normolle D., et al. Characterization of pancreatic tumor motion using cine MRI: surrogates for tumor position should be used with caution. Int J Radiat Oncol Biol Phys 2009, 74(3):884-891.
44. Crane C.H., Antolak J.A., Rosen, et al. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer 2001, 30(3):123-132.
45. Landry J.C., Yang G.Y., Ting J.Y., et al. Treatment of pancreatic cancer tumors with intensity-modulated radiation therapy (IMRT) using the volume at risk approach (VARA): employing dose-volume histogram (DVH) and normal tissue complication probability (NTCP) to evaluate small bowel toxicity. Med Dosim 2002, 27(2):121-129.